arrow
A

Andreas Meisel

charite universitätsmedizin berlin
H指数:75
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infarct-associated oligoclonal T cell expansion in chronic experimental stroke across age, sex, and models

梗死相关寡克隆T细胞扩增在慢性实验性卒中中的年龄、性别和模型差异

2026-09-290
PRE
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

关于在全身性重症肌无力中启动和转换靶向免疫疗法:一项德奥专家意见论文

2026-09-100
OAAI
Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models

双特异性嵌合自身抗体受体T细胞消除重症肌无力模型中的乙酰胆碱受体特异性B细胞

2026-08-200
OAAI
Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland

在用补体抑制剂治疗的神经疾病中实施脑膜炎球菌预防:德国、奥地利和瑞士的专家共识

2026-05-080
PRE
Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

回复函:“补体活性测定作为拉尼珠单抗治疗监测生物标志物的局限性”由Saccà和Pelto就“拉尼珠单抗和依库珠单抗对经典和替代补体通路的抑制作用”一文提出

2026-04-210
OAAI
Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

重症肌无力危象中的补体抑制疗法——来自德国的17例多中心回顾性分析

2026-04-150
OA
A transcriptomic microglia taxonomy across mouse and human pathologies

跨小鼠和人类病理学的转录组小胶质细胞分类学

2026-03-250
OAAI
Patient oriented navigation in stroke and lung cancer patients: Results on feasibility and efficacy of two randomized controlled trials in Germany

以患者为中心的导航在卒中与肺癌患者中的应用:德国两项随机对照试验关于可行性与有效性的结果

2026-03-100
PRE
Assessing post-stroke cognition in pre-clinical models: Lessons and recommendations from a multi-center study

评估卒中后认知功能的预临床模型:一项多中心研究的经验与建议

2025-12-070
OA
Robotic Extended Thymectomy in Late-Onset Myasthenia Gravis: A 21-Year Retrospective Cohort Study of 172 Patients

机器人扩大胸腺切除术在迟发性重症肌无力中的应用:一项对172例患者的21年回顾性队列研究

2025-11-050
OAAI
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

拉伏珠单抗和阿巴西普对经典和替代补体通路的抑制

2025-11-010
OAAI
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls

AXIN1、STAMBP、ST1A1、CDCP1和SIRT2被验证为重症肌无力生物标志物:一项与多发性硬化、慢性炎性脱髓鞘性多发性神经根神经病和对照组的比较蛋白质组学研究

2025-11-010
OAAI